Adage Capital Partners’s Intellia Therapeutics NTLA Stock Holding History

Adage Capital Partners’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-60,000	Closed	-$1.9M	–	909
2023 Q3	$1.9M	Hold	60,000	–	–	﹤0.01%	738
2023 Q2	$2.45M	Sell	60,000 -3,000	-5%	-$122K	0.01%	732
2023 Q1	$2.35M	Sell	63,000 -200,000	-76%	-$7.84M	0.01%	757
2022 Q4	$9.18M	Sell	263,000 -62,000	-19%	-$2.95M	0.02%	657
2022 Q3	$18.2M	Buy	325,000 +149,022	+85%	+$9.24M	0.05%	438
2022 Q2	$9.11M	Buy	175,978 +5,000	+3%	+$254K	0.02%	693
2022 Q1	$12.4M	Sell	170,978 -546,500	-76%	-$46.3M	0.02%	633
2021 Q4	$84.8M	Hold	717,478	–	–	0.15%	147
2021 Q3	$96.3M	Buy	717,478 +254,500	+55%	+$38.5M	0.19%	113
2021 Q2	$75M	Buy	+462,978	New	+$36.1M	0.15%	146

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Adage Capital Partners's NTLA Position: Q4 2023 in Review

Adage Capital Partners sold out of Intellia Therapeutics (NTLA) in Q4 2023, closing a stake of 60,000 shares — an estimated $1.9M sold.

Adage Capital Partners first reported a position in NTLA in Q2 2021 and held it in 10 quarters. The position peaked at $96.3M in Q3 2021. 292 funds tracked by Wall St. Rank hold NTLA as of Q4 2023.

Adage Capital Partners reported no remaining Intellia Therapeutics position as of Q4 2023 after selling out during the quarter.
Adage Capital Partners sold 60,000 Intellia Therapeutics shares in Q4 2023, an estimated $1.9M.
Adage Capital Partners first reported a position in Intellia Therapeutics in Q2 2021 and held it in 10 quarters.
Adage Capital Partners's Intellia Therapeutics position peaked at $96.3M in Q3 2021.
292 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2023.

Based on Adage Capital Partners's 13F filing for Q4 2023, filed 14 Feb 2024.